Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Recent therapeutic advances in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Digestive Disease Week 2001. Novel therapeutic principles in inflammatory bowel disease. 20-23 May 2001, Atlanta, GA, USA

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  4. Evaluation of clinical translatability of the diet-induced obese and biopsy-confirmed gubra amylin mouse model of non-alcoholic steatohepatitis

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. Gluco-metabolic effects of oral and intravenous alcohol administration in men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by insulin resistance, a steady decline in glucose-induced insulin secretion (most likely caused by a progressive decrease in functional beta-cell mass), and inappropriately regulated glucagon secretion; in combination, these effects result in hyperglycemia. In 1958, sulfonylurea (SU) was introduced to the market as one of the first oral treatments for T2DM. Since then, the ability of SU to stimulate the release of insulin from pancreatic beta-cells by the closure of ATP-sensitive K+-channels has been employed as one of the most widespread treatment options for T2DM. However, SUs are associated with weight gain and a risk of hypoglycemia, and the one-track antidiabetic mechanism of SUs often results in patients being treated with additional antidiabetic drugs. In recent studies, SU has proven to be associated with increased beta-cell apoptosis, suggesting that SU may actually accelerate the progressive decrease in beta-cell mass, thereby promoting the need for insulin replacement. In contrast, the newly developed incretin-based therapies for T2DM employ the beta-cell-preserving properties of incretin hormones - glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). More importantly, incretin-based therapies potentiate glucose-stimulated insulin secretion and may restore reduced glucose-induced insulin secretion in T2DM. Furthermore, the insulinotropic effects of GLP-1 and GIP are glucose-dependent, reducing the risk of hypoglycemia. GLP-1 inhibits glucagon secretion and decreases gastrointestinal motility, in turn reducing food intake and body weight. This feature review focuses on the challenges and feasibilities of replacing SU with incretin-based therapy in patients with T2DM.
Original languageEnglish
JournalI Drugs: the Investigational Drugs Journal
Volume11
Issue number7
Pages (from-to)497-501
Number of pages5
ISSN1369-7056
Publication statusPublished - 1 Jul 2008

ID: 32267336